美国IMAXIO
IMAXIO 是一家专注于基因组学和疫苗领域的生物制药公司。基因组学事业部的工作涉及人类健康领域中伴随诊断测试开发的相关项目。IMAXIO 致力于独立开发或与合作伙伴共同开发应用于人类和动物健康领域的重组疫苗。在法国，IMAXIO 已经推出了应对细螺旋体病的人体疫苗 Spirolept。

IMAXIO is a biopharmaceutical company specialized in the areas of genomics and vaccines. The genomic division is involved in programs for the development of companion and diagnostic tests in human health. IMAXIO is developing, both individually and with its partners, recombinant vaccines for applications in both human and animal health. In France, IMAXIO already markets Spirolept, a human vaccine against leptospirosis.